The diagnostic and prognostic value of bone marrow immunostaining in myelodysplastic syndromes

Giorgio Lambertenghi Deliliers, Claudio Annaloro, Davide Soligo, Alessandro Oriani

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Immunohistochemistry has been introduced as a means of increasing the diagnostic accuracy of bone marrow biopsy (BMB) in myelodysplastic syndromes (MDS); more recently the possibility of coupling immunostaining with other investigational techniques has broadened the spectrum of applications to the biology and physiopathology of MDS. Using panels of monoclonal antibodies (MoAbs), various histological classifications of MDS have been proposed as an alternative to the FAB criteria. The use of Lineage-specific MoAbs has allowed a deeper insight into the dysplastic features of early hematopoietic precursors. The study of various gene products involved in the regulation of cell growth, proliferation and sensitivity to antineoplastic drugs, has revealed significant differences between MDS and morphologically-related disorders, particularly acute myelogenous leukemias (AML); these can be considered markers of a biological difference between the two groups of disorders and deserve consideration when designing therapeutic strategies for MDS, Both an increase in the percentage of cell positivity for the CD34 glycoprotein and a tendency of positive cells towards forming aggregates have been shown to be reliable predictors of leukemic transformation and survival, irrespective of the FAB subtype; furthermore, CD34 positivity has also proved to be a better prognostic factor than the presence of the abnormal localization of immature precursors (ALIP) on BMB. Finally, the simultaneous occurrence of 'large' and CD34 positive aggregates can be proposed as a means of recognizing MDS patients with an exceedingly unfavourable prognosis, and who are therefore suitable for early aggressive therapy.

Original languageEnglish
Pages (from-to)231-239
Number of pages9
JournalLeukemia and Lymphoma
Volume28
Issue number3-4
Publication statusPublished - 1998

Fingerprint

Myelodysplastic Syndromes
Bone Marrow
Monoclonal Antibodies
Biopsy
Secondary Prevention
Acute Myeloid Leukemia
Antineoplastic Agents
Glycoproteins
Biomarkers
Immunohistochemistry
Cell Proliferation
Survival
Growth
Genes

Keywords

  • Bone marrow biopsy
  • Immunohistochemistry
  • Monoclonal antibodies
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Deliliers, G. L., Annaloro, C., Soligo, D., & Oriani, A. (1998). The diagnostic and prognostic value of bone marrow immunostaining in myelodysplastic syndromes. Leukemia and Lymphoma, 28(3-4), 231-239.

The diagnostic and prognostic value of bone marrow immunostaining in myelodysplastic syndromes. / Deliliers, Giorgio Lambertenghi; Annaloro, Claudio; Soligo, Davide; Oriani, Alessandro.

In: Leukemia and Lymphoma, Vol. 28, No. 3-4, 1998, p. 231-239.

Research output: Contribution to journalArticle

Deliliers, GL, Annaloro, C, Soligo, D & Oriani, A 1998, 'The diagnostic and prognostic value of bone marrow immunostaining in myelodysplastic syndromes', Leukemia and Lymphoma, vol. 28, no. 3-4, pp. 231-239.
Deliliers, Giorgio Lambertenghi ; Annaloro, Claudio ; Soligo, Davide ; Oriani, Alessandro. / The diagnostic and prognostic value of bone marrow immunostaining in myelodysplastic syndromes. In: Leukemia and Lymphoma. 1998 ; Vol. 28, No. 3-4. pp. 231-239.
@article{af31f246511e422bbb58bdf43ace4421,
title = "The diagnostic and prognostic value of bone marrow immunostaining in myelodysplastic syndromes",
abstract = "Immunohistochemistry has been introduced as a means of increasing the diagnostic accuracy of bone marrow biopsy (BMB) in myelodysplastic syndromes (MDS); more recently the possibility of coupling immunostaining with other investigational techniques has broadened the spectrum of applications to the biology and physiopathology of MDS. Using panels of monoclonal antibodies (MoAbs), various histological classifications of MDS have been proposed as an alternative to the FAB criteria. The use of Lineage-specific MoAbs has allowed a deeper insight into the dysplastic features of early hematopoietic precursors. The study of various gene products involved in the regulation of cell growth, proliferation and sensitivity to antineoplastic drugs, has revealed significant differences between MDS and morphologically-related disorders, particularly acute myelogenous leukemias (AML); these can be considered markers of a biological difference between the two groups of disorders and deserve consideration when designing therapeutic strategies for MDS, Both an increase in the percentage of cell positivity for the CD34 glycoprotein and a tendency of positive cells towards forming aggregates have been shown to be reliable predictors of leukemic transformation and survival, irrespective of the FAB subtype; furthermore, CD34 positivity has also proved to be a better prognostic factor than the presence of the abnormal localization of immature precursors (ALIP) on BMB. Finally, the simultaneous occurrence of 'large' and CD34 positive aggregates can be proposed as a means of recognizing MDS patients with an exceedingly unfavourable prognosis, and who are therefore suitable for early aggressive therapy.",
keywords = "Bone marrow biopsy, Immunohistochemistry, Monoclonal antibodies, Myelodysplastic syndromes",
author = "Deliliers, {Giorgio Lambertenghi} and Claudio Annaloro and Davide Soligo and Alessandro Oriani",
year = "1998",
language = "English",
volume = "28",
pages = "231--239",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "3-4",

}

TY - JOUR

T1 - The diagnostic and prognostic value of bone marrow immunostaining in myelodysplastic syndromes

AU - Deliliers, Giorgio Lambertenghi

AU - Annaloro, Claudio

AU - Soligo, Davide

AU - Oriani, Alessandro

PY - 1998

Y1 - 1998

N2 - Immunohistochemistry has been introduced as a means of increasing the diagnostic accuracy of bone marrow biopsy (BMB) in myelodysplastic syndromes (MDS); more recently the possibility of coupling immunostaining with other investigational techniques has broadened the spectrum of applications to the biology and physiopathology of MDS. Using panels of monoclonal antibodies (MoAbs), various histological classifications of MDS have been proposed as an alternative to the FAB criteria. The use of Lineage-specific MoAbs has allowed a deeper insight into the dysplastic features of early hematopoietic precursors. The study of various gene products involved in the regulation of cell growth, proliferation and sensitivity to antineoplastic drugs, has revealed significant differences between MDS and morphologically-related disorders, particularly acute myelogenous leukemias (AML); these can be considered markers of a biological difference between the two groups of disorders and deserve consideration when designing therapeutic strategies for MDS, Both an increase in the percentage of cell positivity for the CD34 glycoprotein and a tendency of positive cells towards forming aggregates have been shown to be reliable predictors of leukemic transformation and survival, irrespective of the FAB subtype; furthermore, CD34 positivity has also proved to be a better prognostic factor than the presence of the abnormal localization of immature precursors (ALIP) on BMB. Finally, the simultaneous occurrence of 'large' and CD34 positive aggregates can be proposed as a means of recognizing MDS patients with an exceedingly unfavourable prognosis, and who are therefore suitable for early aggressive therapy.

AB - Immunohistochemistry has been introduced as a means of increasing the diagnostic accuracy of bone marrow biopsy (BMB) in myelodysplastic syndromes (MDS); more recently the possibility of coupling immunostaining with other investigational techniques has broadened the spectrum of applications to the biology and physiopathology of MDS. Using panels of monoclonal antibodies (MoAbs), various histological classifications of MDS have been proposed as an alternative to the FAB criteria. The use of Lineage-specific MoAbs has allowed a deeper insight into the dysplastic features of early hematopoietic precursors. The study of various gene products involved in the regulation of cell growth, proliferation and sensitivity to antineoplastic drugs, has revealed significant differences between MDS and morphologically-related disorders, particularly acute myelogenous leukemias (AML); these can be considered markers of a biological difference between the two groups of disorders and deserve consideration when designing therapeutic strategies for MDS, Both an increase in the percentage of cell positivity for the CD34 glycoprotein and a tendency of positive cells towards forming aggregates have been shown to be reliable predictors of leukemic transformation and survival, irrespective of the FAB subtype; furthermore, CD34 positivity has also proved to be a better prognostic factor than the presence of the abnormal localization of immature precursors (ALIP) on BMB. Finally, the simultaneous occurrence of 'large' and CD34 positive aggregates can be proposed as a means of recognizing MDS patients with an exceedingly unfavourable prognosis, and who are therefore suitable for early aggressive therapy.

KW - Bone marrow biopsy

KW - Immunohistochemistry

KW - Monoclonal antibodies

KW - Myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=0031929506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031929506&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 231

EP - 239

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3-4

ER -